Yıl: 2013 Cilt: 13 Sayı: 1 Sayfa Aralığı: 39 - 44 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study

Öz:
Amaç: Koroner yavaş akım (KYA) epikardiyal koroner arterlerin obstrüktif hastalık olmaksızın yavaş dolması ile karakterize bir durumdur. CD40/ CD40 ligandı (CD40L) sistemi artmış enflamasyon ve protrombotik yatkınlık sebebiyle aterosklerozla yakın ilişkili gibi görünmektedir. Biz, CD40/ CD40L ikilisinin indirekt bir göstergesi olan serum çözünmüş CD40 (çCD40) düzeylerinin KYA ile ilişkisini araştırmayı hedefledik. Yöntemler: Çalışmamız gözlemsel ve kesitsel nitelikte olup, koroner arter hastalığı şüphesi ile koroner anjiyografi yapılan ve değişken akım hızlarında normal koroner arterler saptanan 70 hasta içeriyordu. KYA, çCD40 ve C-reaktif protein (CRP) arası ilişki incelendi. Çalışmaya KYA’sı olan 50 hasta (ort. yaş 56±10) ve koroner akımı ve koroner arterleri normal (NKA) 20 yaş-cinsiyeti uyumlu kontrol hastası (Ort. yaş 55±10) alındı. KYA’ın öngörücülerini belirlemede lojistik regresyon analizi kullanıldı. Bulgular: KYA ve NKA grubu arasında klinik karakteristikler ve CRP düzeyleri açısından farklılık saptanmadı. Serum çCD40 düzeyi KYA grubunda NKA grubuna göre anlamlı düzeyde yüksek (74±31 - 59±16 pg/mL, p=0.014) saptandı. Çok değişkenli analizde, ortalama koroner çapı kuvvetli (OR: 7.358, %95 CI: 1.990-27.20, p=0.003) ve çCD40 (OR: 1.044, %95 CI: 1.006-1.084, p=0.023) düzeyi zayıf bir KYA belirteci olarak saptandı. Sonuç: Çalışmamızda, KYA akım hastalarında artmış çCD40 konsantrasyonun var olduğunu ilk defa ortaya koyduk. Biz, KYA’nın altta yatan patofizyolojik sürecini netleştiremesek de, bulgularımızın KYA fenomeni gelişiminde çCD40/CD40L sisteminin özgül rollerinin daha iyi anlaşılmasında öncül rol oynayabileceğine inanıyoruz.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Koroner yavaş akım hastalarında kanda artmış CD40 konsantrasyonu: Bir gözlemsel çalışma

Öz:
Objective: Slow coronary flow (SCF) is an angiographic finding characterized with delayed opacification of epicardial coronary arteries without obstructive coronary disease. CD40/CD40 ligand (CD40L) signaling seems closely related to atherosclerosis due to increased inflammation and prothrombotic state. We investigated whether soluble CD40 (sCD40), an indirect marker of CD40/CD40L dyad, is related to SCF. Methods: The present study was cross-sectional and observational, consisting of seventy individuals who underwent coronary angiography with suspicion of CAD and had angiographically normal coronary arteries of varying coronary flow rates. The relationship between sCD40, C-reactive protein (CRP) and SCF phenomenon was investigated. Fifty patients with isolated SCF (mean age: 56±10 years) and 20 age- and gender-matched control participants with normal coronary flow (NCF) and normal coronary arteries (NCA), (mean age: 55±10 years) were included in the study. We used logistic regression analysis to determine the predictors of SCF. Results: The clinical characteristics were not statistically significant different between SCF and NCA group. Serum CRP levels were also simi- lar between two groups. Serum sCD40 level was significantly higher in the SCF group compared to control group (74±31 vs. 59±16 pg/mL, p=0.014). In multiple regression analyses, mean coronary diameter strongly (OR: 7.358, 95% CI: 1.990-27.20, p=0.003) and sCD40 (OR: 1.044, 95% CI: 1.006-1.084, p=0.023) weakly predicted SCF. Conclusion: This study revealed, significantly increased serum sCD40 levels in patients with SCF. Although we cannot conclude the underlying pathological process of SCF, we believe that these findings may be pivotal for further studies searching the specific roles of CD40/CD40L signal- ing on SCF phenomenon in coronary vasculature.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J 1972; 84: 66-71. [CrossRef]
  • 2. Goel PK, Gupta SK, Agarwal A, Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52: 507-14. [CrossRef]
  • 3. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996; 37: 375-81. [CrossRef]
  • 4. Cin VG, Pekdemir H, Camsar A, Çiçek D, Akkuş MN, Parmaksız T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44: 907-19. [CrossRef]
  • 5. Sezgin AT, Sığırcı A, Barutçu I, Topal E, Sezgin N, Özdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14: 155-61. [CrossRef]
  • 6. Rıza Erbay A, Turhan H, Yaşar AS, Ayaz S, Şahin O, Senen K, et al. Elevated level of plasma homocysteine in patients with slow coronary flow. Int J Cardiol 2005; 102: 419-23. [CrossRef]
  • 7. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986; 74: 964-72. [CrossRef]
  • 8. Fragasso G, Chierchia SL, Arioli F, Carandente O, Gerosa S, Carlino M, et al. Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol 2009; 137: 137-44. [CrossRef]
  • 9. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80-2. [CrossRef]
  • 10. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Förster R, Müller- Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4. [CrossRef]
  • 11. Schonbeck U, Libby P The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43. [CrossRef]
  • 12. Santilli F, Basili S, Ferroni P Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-68. [CrossRef]
  • 13. Gibson CM, Cannon CP Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88. [CrossRef]
  • 14. Kurtoğlu N, Akcay A, Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001; 87: 777-9, A8.
  • 15. Pekdemir H, Polat G, Cin VG, Camsari A, Çicek D, Akkuş MN, et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 2004; 97: 35-41. [CrossRef]
  • 16. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. Circulation 2001; 104: 2401-6. [CrossRef]
  • 17. Li JJ, Xu B, Li ZC, Qian J, Wei BQ. Is slow coronary flow associated with inflammation? Med Hypotheses 2006; 66: 504-8. [CrossRef]
  • 18. Turhan H, Saydam GS, Erbay AR, Ayaz S, Yaşar AS, Aksoy Y, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 2006; 108: 224-30. [CrossRef]
  • 19. Lanza GA, Andreotti F, Sestito A, Sciahbasi A, Crea F, Maseri A. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001; 22: 1924-30. [CrossRef]
  • 20. Gökçe M, Kaplan S, Tekelioğlu Y, Erdoğan T, Küçükosmanoğlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 2005; 28: 145-8. [CrossRef]
  • 21. Çamsarı A, Pekdemir H, Çicek D, Polat G, Akkuş MN, Döven O, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003; 67: 1022-8. [CrossRef]
  • 22. Yıldız A, Gür M, Yılmaz R, Demirbağ R, Polat M, Selek S, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008; 197: 257-63. [CrossRef]
  • 23. Enli Y, Türk M, Akbay R, Evrengül H, Tanrıverdi H, Kuru O, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther 2008; 25: 37-44. [CrossRef]
  • 24. Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology 2012; 121: 197-203. [CrossRef]
  • 25. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med2002; 12: 27-32. [CrossRef]
  • 26. Kiener PA, Moran-Davis P Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155: 4917-25.
  • 27. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156: 3952-60.
  • 28. Zhou L, Stordeur P de Lavareille A, Thielemans K, Capel P Goldman M, et al. CD40 engagement on endothelial cells promotes tissue factor- dependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.
  • 29. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106: 981-6. [CrossRef]
  • 30. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A 2001; 98: 1751-6. [CrossRef]
  • 31. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 2003; 278: 32801-9. [CrossRef]
  • 32. De Paoli P Cozzi M, Tedeschi R, Gloghini A, Cilia AM, van Kooten C, et al. High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. Cytometry 1997; 30: 33-8. [CrossRef]
  • 33. Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 755-66. [CrossRef]
  • 34. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation, 2002; 106: 2888-93. [CrossRef]
  • 35. Arı H, Arı S, Erdoğan E, Tiryakioğlu O, Huysal K, Koca V, et al. The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyol Dern Ars 2010; 38: 327-33.
  • 36. Yazıcı M, Aksakal E, Demircan S, Şahin M, Sağkan O. Is slow coronary flow related with inflammation and procoagulant state? Anadolu Kardiyol Derg 2005; 5: 3-7.
  • 37. Xia S, Deng SB, Wang Y, Xiao J, Du JL, Zhang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels 2011; 26: 480-6. [CrossRef]
  • 38. Barutçu I, Sezgin AT, Sezgin N, Güllü H, Esen AM, Topal E, et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology 2007; 58: 401-7. [CrossRef]
APA Durakoglugil M, KOCAMAN S, ÇETİN M, Kırbaş A, ÇANĞA A, ERDOĞAN T, çiçek y (2013). Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. , 39 - 44.
Chicago Durakoglugil Murtaza Emre,KOCAMAN Sinan Altan,ÇETİN Mustafa,Kırbaş Aynur,ÇANĞA Aytun,ERDOĞAN Turan,çiçek yüksel gülen Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. (2013): 39 - 44.
MLA Durakoglugil Murtaza Emre,KOCAMAN Sinan Altan,ÇETİN Mustafa,Kırbaş Aynur,ÇANĞA Aytun,ERDOĞAN Turan,çiçek yüksel gülen Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. , 2013, ss.39 - 44.
AMA Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. . 2013; 39 - 44.
Vancouver Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. . 2013; 39 - 44.
IEEE Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y "Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study." , ss.39 - 44, 2013.
ISNAD Durakoglugil, Murtaza Emre vd. "Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study". (2013), 39-44.
APA Durakoglugil M, KOCAMAN S, ÇETİN M, Kırbaş A, ÇANĞA A, ERDOĞAN T, çiçek y (2013). Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyoloji Dergisi, 13(1), 39 - 44.
Chicago Durakoglugil Murtaza Emre,KOCAMAN Sinan Altan,ÇETİN Mustafa,Kırbaş Aynur,ÇANĞA Aytun,ERDOĞAN Turan,çiçek yüksel gülen Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyoloji Dergisi 13, no.1 (2013): 39 - 44.
MLA Durakoglugil Murtaza Emre,KOCAMAN Sinan Altan,ÇETİN Mustafa,Kırbaş Aynur,ÇANĞA Aytun,ERDOĞAN Turan,çiçek yüksel gülen Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyoloji Dergisi, vol.13, no.1, 2013, ss.39 - 44.
AMA Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyoloji Dergisi. 2013; 13(1): 39 - 44.
Vancouver Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyoloji Dergisi. 2013; 13(1): 39 - 44.
IEEE Durakoglugil M,KOCAMAN S,ÇETİN M,Kırbaş A,ÇANĞA A,ERDOĞAN T,çiçek y "Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study." Anadolu Kardiyoloji Dergisi, 13, ss.39 - 44, 2013.
ISNAD Durakoglugil, Murtaza Emre vd. "Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study". Anadolu Kardiyoloji Dergisi 13/1 (2013), 39-44.